Megahed M, Scharffetter-Kochanek K
Department of Dermatology, Heinrich-Heine University, Düsseldorf, Germany.
Arch Dermatol Res. 1994;286(1):35-46. doi: 10.1007/BF00375841.
The treatment of epidermolysis bullosa acquisita (EBA) is difficult and often disappointing. We report on the successful treatment of two EBA patients with colchicine. The drug was administered orally at an initial dose of 2 mg/day. After 2 weeks of therapy a dramatic improvement was observed. Most of the cutaneous and buccal mucosal lesions had healed and both of the patients were able to go about their normal daily activities. In the first patient the disease was refractory to dapsone alone or combined with steroids. In the second patient no other treatment was tried. After 6 months a maintenance dose of 1 mg/day colchicine was given. The disease had remained stable in both patients at the time of writing for more than 8 months. No side effects were observed. We suggest that colchicine may be a helpful and safe drug for patients with EBA.
获得性大疱性表皮松解症(EBA)的治疗困难且常常令人失望。我们报告了两例使用秋水仙碱成功治疗EBA患者的病例。该药物口服给药,初始剂量为2毫克/天。治疗2周后观察到显著改善。大多数皮肤和口腔黏膜病变已愈合,两名患者均能够进行正常的日常活动。首例患者单独使用氨苯砜或联合使用类固醇治疗均无效。第二例患者未尝试其他治疗方法。6个月后给予1毫克/天的秋水仙碱维持剂量。在撰写本文时,两名患者的病情均保持稳定超过8个月。未观察到副作用。我们认为秋水仙碱对于EBA患者可能是一种有用且安全的药物。